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Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease. Repetitive injury and
reprogramming of the lung epithelium are thought to be critical drivers of disease progression, contributing to
fibroblast activation, extracellular matrix remodeling, and subsequently loss of lung architecture and function. To
date, Pirfenidone and Nintedanib are the only approved drugs known to decelerate disease progression, however, if
and how these drugs affect lung epithelial cell function, remains largely unexplored.
Methods: We treated murine and human 3D ex vivo lung tissue cultures (3D-LTCs; generated from precision cut
lung slices (PCLS)) as well as primary murine alveolar epithelial type II (pmATII) cells with Pirfenidone or Nintedanib.
Murine 3D-LTCs or pmATII cells were derived from the bleomycin model of fibrosis. Early fibrotic changes were
induced in human 3D-LTCs by a mixture of profibrotic factors. Epithelial and mesenchymal cell function was
determined by qPCR, Western blotting, Immunofluorescent staining, and ELISA.
Results: Low μM concentrations of Nintedanib (1 μM) and mM concentrations of Pirfenidone (2.5 mM) reduced
fibrotic gene expression including Collagen 1a1 and Fibronectin in murine and human 3D-LTCs as well as pmATII
cells. Notably, Nintedanib stabilized expression of distal lung epithelial cell markers, especially Surfactant Protein C in
pmATII cells as well as in murine and human 3D-LTCs.
Conclusions: Pirfenidone and Nintedanib exhibit distinct effects on murine and human epithelial cells, which
might contribute to their anti-fibrotic action. Human 3D-LTCs represent a valuable tool to assess anti-fibrotic
mechanisms of potential drugs for the treatment of IPF patients.
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Background
Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease
with a median survival of 3–5 years [1]. Repetitive lung
epithelial cell injury and reprogramming along with
(myo)fibroblast activation and ECM production have
been proposed to be critically involved in IPF pathogen-
esis [1–3]. Within the distal lung, alveolar epithelial type
(AT) II cells have been described to undergo significant
phenotypic and functional changes upon fibrotic lung in-
jury [4, 5], including endoplasmatic reticulum stress [6],
mitochondrial dysfunction [7], or senescence [8], More-
over, these cells have been reported to release a variety
of profibrotic mediators, such as Transforming growth
factor (TGF)-β [9], IL-1β [10], sphingosine 1-phosphate
(S1P) [11], or WNT ligands [12, 13]. Altogether, these
studies support the notion that targeting the dysfunc-
tional epithelium might be a promising therapeutic strat-
egy for the treatment of IPF.
To date, Nintedanib and Pirfenidone are the only ap-
proved drugs known to decelerate disease progression
[14, 15]. Nintedanib (BIBF-1120) is a multi-tyrosine kin-
ase inhibitor and is known to inhibit the receptor ki-
nases of platelet-derived growth factor (PDGF),
fibroblast growth factor (FGF) and vascular endothelial
growth factor (VEGF), which are all thought to play an
important role in the pathogenesis of IPF [16]. Its
anti-fibrotic activity has been demonstrated in multiple
animal models of lung fibrosis and in in vitro assays [16–
19]. In particular, Nintedanib has been shown to inhibit
various fibroblast functions, such as proliferation, fibro-
blast to myofibroblast differentiation, and extracellular
matrix (ECM) production [16–19]. However, it has been
previously acknowledged that non-receptor kinases or tar-
gets not yet identified and/or effects on cells other than fi-
broblasts could contribute to the anti-fibrotic properties
of Nintedanib [16, 20, 21]. Pirfenidone (5-methyl-1-phe-
nyl-2-(1H)-pyridone) exhibits anti-fibrotic activity not
only in the lung, but further in kidney, hepatic, and car-
diac fibrosis [22–24]. Pirfenidone has anti-oxidant,
anti-fibrotic and anti-inflammatory properties as shown in
several in vitro and in vivo studies [22, 23].
Three-dimensional (3D) models, which allow and fa-
cilitate the study of primary lung cells in the intact lung
structure and microenvironment, have recently begun to
emerge. 3D-lung tissue cultures (3D-LTCs; precision cut
lung slices (PCLS)) have been traditionally used for
studying airway contraction, but have only recently been
applied to more extended mechanistic studies ex vivo.
While one major benefit is that they allow for an overall
reduction of animals required for experimentation, they
also permit studies directly in human tissue [25–29].
3D-LTCs can be used to analyze human tissue-level re-
sponses to anti-fibrotic drugs, which might help to bet-
ter understand the mechanisms and functional effects of
drugs in human tissue and thus might better predict
clinical efficacy. Recently, potential anti-fibrotic drugs
have been tested on PCLS derived from IPF explants
[26]. However, explanted IPF tissue is rare and repre-
sents end-stage disease at which ongoing disease mecha-
nisms may differ significantly from earlier changes.
Thus, validation of potential clinical compounds might
benefit from human models, which mimic earlier stages
of the disease. We have recently developed a novel
model of early fibrosis-like changes in human 3D-LTCs
allowing the evaluation of early pathomechanisms of IPF
[25]. The effects of Nintedanib and Pirfenidone on hu-
man 3D-LTCs ex vivo, especially on lung epithelial cell
function, have not yet been explored.
Methods
Human tissue
Tumor-free lung tissue from lung cancer resections of
patients without a co-morbidity of IPF/ILD was used to
generate human 3D lung tissue cultures (3D-LTCs) as
previously described [25, 28]. Human tissue has been
obtained from the Comprehensive Pneumology Center
cohort of the BioArchive CPC-M at the University Hos-
pital Grosshadern of the Ludwig Maximilian University
(Munich, Germany) and by the Asklepios Biobank of
Lung Diseases (Gauting, Germany). Participants pro-
vided written informed consent to participate in this
study, in accordance with approval by the local ethics
committee of the LMU, Germany (Project 333-10,
455-12). Tumor-free tissue from lung cancer resection
surgeries of patients without an IPF/ILD diagnosis was
used comprising the following: 2 patients (1 male
62 years, 1 female, 80 years) with squamous cell carcin-
oma and 1 patient with a carcinoid tumor of the lung
(male, 48 years). No information on smoking history was
available for these patients. Absence of IPF/ILD was
confirmed by CT and pathology.
Animal experiment
Pathogen-free female C57BL/6 mice (6–8 wk. old) pur-
chased from Charles River were used in all studies. The
mice were housed in rooms with constant humidity and
temperature with 12 h light cycles and had free access to
water and food. All experiments were performed in ac-
cordance with the guidelines of the ethics committee of
the Helmholtz Zentrum Munich (Germany) and ap-
proved by the regional council of Upper Bavaria
Germany (Project 55.2–1-54-2532-88-12). For the induc-
tion of experimental fibrosis, a single dose of Bleomycin
(2 U/kg body weight; Bleomycin sulfate, Almirall, Spain,
dissolved in 50 μl sterile PBS) was intratracheally admin-
istered using the Micro-Sprayer Aerosolizer (Penn-Cen-
tury, Wyndmoor, PA). Control mice received 50 μl PBS.
Fourteen days after instillation the mice were sacrificed
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and the lungs were harvested for the generation of pmA-
TII cells or 3D-LTCs.
Cell culture
The pmATII cells were isolated from mice as previously
described [8]. The pmATII cells were seeded in 12
well-tissue culture plates and cultured in DMEM-F12
supplemented with 10% FCS, 2 mM 1-glutamine, 1% peni-
cillin/streptomycin, 3.6 mg/ml glucose and 10 mM HEPES
for 24 h to allow attachment. Cells were then cultured for
12 h in fresh 0.1% FCS containing medium. Subsequently,
cells were pre-treated with Nintedanib (1 μM) (Selleck,
Houston, TX) or Pirfenidone (500 μM) (Selleck, Houston,
TX) or respective DMSO control for 48 h.
Human and murine 3D-lung tissue culture (3D-LTCs) ex
vivo
Human and murine 3D-LTCs and 4 mm-punches
thereof were generated as previously described [25, 28].
The amount of slices generated from one mouse lung
varied between 18 and 25 slices, determining the
amount of further downstream analysis. The 3D-LTCs
were cultured in DMEM-F12 containing 0.1% FCS and
1% penicillin/streptomycin. 3D-LTCs obtained from
mice subjected to PBS or Bleomycin were stimulated ei-
ther with Nintedanib (0.1 μM, 1 μM, 10 μM) or Pirfeni-
done (100 μM, 500 μM, 2.5 mM) for 48 h.
Human 3D-LTCs were treated with a fibrosis cocktail
(FC) consisting of TGF-β, Platelet-derived growth factor
(PDGF)-AB, tumor necrosis factor (TNF)-α and Lyso-
phosphatidic acid (LPA) [25]. Briefly, slices and 4-mm
biopsy punches were treated with FC or control cocktail
(CC) for 48 h followed by the co-treatment of Nintedanib
(1 μM) or Pirfenidone (500 μM) with FC or CC for 72 h
(Fig. 4a). Supernatants from punches were pooled for each
condition and stored at − 80 °C for further analysis. A
WST-1 assay was performed as previously described [25].
Punches were fixed with 4% paraformaldehyde (PFA) for
30 min and subsequently washed with 1 X DPBS. Slices
were snap-frozen in liquid nitrogen and stored at − 80 °C.
Immunofluorescence (IF)
IF was performed as previously described [25, 28].
Briefly, 3D-LTCs were fixed with acetone/methanol
(AppliChem, Germany) for 20 min or as indicated other-
wise, blocked with 5% bovine serum albumin (Sigma Al-
drich, UK) in PBS for 1 h at RT and subsequently
incubated in primary antibody diluted in PBS containing
0.1% BSA over night at 4 °C followed by secondary anti-
body incubation for 2 h at room temperature and DAPI
(Roche, Switzerland) stain for 10 min. Images were
obtained using LSM710 confocal microscope (Zeiss,
Germany). 3D images were reconstructed using
IMARIS× 64 (v9.0; Bitplane, Zurich, Switzerland).
RNA isolation and quantitative (q)RT-PCR
Two to three 3D-LTCs were pooled, snap frozen in li-
quid nitrogen and homogenized using a tissue lyser as
previously described [25, 28]. Peqlab Total RNA Kit
(Peqlab, Germany) was used for total RNA isolation
from cells and murine 3D-LTCs with modifications of
the manufacturer’s instructions. Total RNA from human
3D-LTCs was extracted using the RNeasy Fibrous tissue
kit (Quiagen, Germany) with Peqlab DNA removing col-
umns prior to RNA binding. The RNA concentration
and quality was assessed using NanoDrop spectropho-
tometer (Thermo Fisher Scientific, Germany). qRT-PCR
was performed using SYBR Green (Roche, Switzerland)
and the LC480 Light Cycler (Roche, Switzerland). HPRT
for mouse and human was used as a reference gene in
all qRT-PCR reactions. The relative gene expression is
defined as ΔCp value (ΔCp = (Cp Hprt)-(Cp gene of
interest)). Logfold change as ΔΔCp = ΔCp (treatment)
-ΔCp(Control). The following primer sequences were
used: mFn1-F,5’-GGTGTAGCACAACTTCCAATTACG
-3′; mFn1-R, 5’-GGAATTTCCGCCTCGAGTCT-3′;
mCol1a1-F, 5’-CCAAGAAGACATCCCTGAAGTCA-3′,
mCol1a1-R, 5’-TGCACGTCATCGCACACA-3′; mSftpc-
F, 5’-AGCAAAGAGGTCCTGATGGA-3′; mSftpc-R, 5’
-GAGCAGAGCCCCTACAATCA-3′; mT1a-F, 5’-ACAG
GTGCTACTGGAGGGCTT-3′; mT1a-R, 5’-TCCTCTA
AGGGAGGCTTCGTC-3′; mNkx2.1-F, 5′- AGGACA
CCATGCGGAACAG-3′; mNkx2.1-R, 5’-CCATGCCGC
TCATATTCATGC-3′; mHopx-F, 5’-TCTCCATCCTTA
GTCAGACGC-3′; mHopx-R, 5’-GGGTGCTTGTTGAC
CTTGTT-3′; huCDH1-F, 5’-ATACACTCTCTTCTCTC
ACGCTGTGT-3′; huCDH1-R, 5’-CATTCTGATCGG
TTACCGTGATC-3′; huZO1-F, 5’-TCTGAGCCTGTAA
GAGAGGAC-3′; huZO1-R, 5’-GCTTCTGCTTTCTG
TTGAGAGG-3′; huSFTPC-F, 5’-GCCCAGTGCACCTG
AAACGC-3′; huSFTPC-R, 5’-TCTCCAGAACCATC
TCCGTGTGT-3′; hNKX2.1-F, 5’-AGCACACGACTCC
GTTCTC-3′; hNKX2.1-R, 5’-GCCCACTTTCTTGTAG
CTTTCC-3′.
Immunoblotting
Pulverized 3D-LTCs were lysed in T-PER lysis buffer
(Thermo Fisher Scientific, Germany) containing proteinase
and phosphatase inhibitors (Roche, Switzerland). Protein
concentration was assessed using the BCA assay (Thermo
Fisher Scientific, Germany) according to the manufacturer’s
instructions. 15 μg of total protein was separated on
SDS-polyacrylamide gels and transferred to PVDF mem-
branes (Biorad, USA). The membranes were blocked in 5%
nonfat dry milk (Applichem, Germany) and incubated with
the primary antibody (at 4 °C overnight followed by 1 h at
RT). Subsequently the blots were incubated with respective
secondary, HRP-conjugated, antibody (GE-Healthcare) for
1 h, washed and visualized using chemiluminescence
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reagents (Pierce ECL, Thermo Fisher Scientific, Germany)
with the ChemiDocTMXRS+ system. Analysis of secreted
collagen was performed by concentrating 200 μl of
supernatant from the same number of 4-mm punches
generated from 3D-LTCs in each group using Nano-
sep 10 K OMEGA columns (Pall Corporation, MI,
USA) followed by dilution in 60 μl lysis buffer and as
previously described [25].
Antibodies
Primary antibodies for immunoblotting and immuno-
fluorescence were as follows: anti proSP-C, ab40879
(Abcam, UK; WB 1:1000, IF 1:200); anti Collagen1, 600–
401-103 (Rockland, USA; WB 1:1000, IF 1:200)); anti fi-
bronectin ((H-300) (sc-9068, SantaCruz, Heidelberg,
Germany; IF 1:200); anti E-cad (610181, BD, Franklin
Lakes, NJ, USA, IF 1:200); anti aSMA (ab5694, Abcam,
UK, IF 1:100); anti β-actin, A3854 (Sigma Aldrich, UK;
WB 1:25000). Alexafluor conjugated (488, 555 or 647)
anti-mouse and anti-rabbit secondary antibodies
(Thermo Fisher Scientific, Germany) were used for IF.
ELISA
Supernatants were taken from cultures of murine and
human 3D-LTCs. Secreted protein content was deter-
mined by enzyme-linked immunosorbent assay (ELISA)
according to the manufacturer’s instructions (m/hWISP1
– DY1627, R&D, MN, USA; mSP-C - CSB-E12639m,
Cusabio, MD, USA; hSP-C - CSB-E10135h, Cusabio,
MD, USA).
Statistical analysis
All data is presented as mean ± SEM and was generated
using GraphPad Prism 5. Statistical significance was
evaluated with either Wilcoxon signed-rank test,
Mann-Whitney U test or repeated-measures one-way
ANOVA followed by Newmann-Keuls multiple compari-
son test or two-way ANOVA followed by Sidak’s mul-
tiple comparison test or significance of log-fold change
was evaluated with one-sample t-tests in comparison to
a hypothetical value of 0. Differences were considered to
be statistically significant when P < 0.05.
Results
Nintedanib and Pirfenidone have both been shown to
exhibit anti-fibrotic capacities in animal models of lung
fibrosis in vivo. As our ultimate goal was to test the ef-
fect of the compounds in an ex vivo model of human
pulmonary fibrosis, we sought to establish the feasibility
of this approach by using murine ex vivo models. Mice
were subjected to intratracheal bleomycin administration
and 3D-LTCs were generated after 14 days of in vivo fi-
brosis development (Additional file 1: Figure S1), repre-
senting a time point with established fibrosis where
preclinical testing of potential anti-fibrotic drugs has
been recommended [30]. We first established baseline
characteristics of freshly generated healthy and fibrotic
murine 3D-LTCs and found that 3D-LTCs derived from
fibrotic mice maintained the fibrotic lung structure ex
vivo, as indicated by dense staining of collagen and in-
creased alpha-SMA, accompanied by decreases in
E-cadherin expression, thus demonstrating that 3D-LTC
generation does not significantly affect baseline differ-
ences (Fig. 1a). To further characterize the fibrotic
phenotype of 3D-LTCs in culture, fibrotic markers were
analyzed after 48 h. As shown in Fig. 1b, the expression
of the mesenchymal marker genes Fibronectin 1 (Fn1)
and Collagen (Col) 1a1 were both significantly upregu-
lated compared to the PBS control. In line with this, the
secretion of total collagen analysed by Western Blotting
was significantly increased (Fig. 1c). Furthermore, we
found that the secretion of Wnt1-inducible signaling
protein (WISP) 1, a protein increased in the distal pul-
monary epithelium of fibrotic mice and in human fibro-
sis, was significantly upregulated at 48 h (Fig. 1d) [8, 13].
Given that the fibrotic phenotype is maintained in ex
vivo 3D-LTCs, we next analyzed the therapeutic effects
of Pirfenidone and Nintedanib (Fig. 1e, f ). We observed
dose-dependent effects for both compounds. Nintedanib
significantly downregulated mRNA levels of Fn1 and
Col1a1 at 1 μM (− 0.94 ± 0.25 and − 1.51 ± 0.99, respect-
ively; log fold change compared to control), while Pirfe-
nidone significantly downregulated Col1a1 at 2.5 mM
(− 1.36 ± 1.39 and − 1.95 ± 1.07, respectively; log fold
change compared to control). Furthermore, the secretion
of collagen, as analyzed by Western blotting, showed a
trend towards downregulation upon Nintedanib treat-
ment but was not changed by Pirfenidone treatment in
fibrotic 3D-LTCs (0.61 ± 0.16 and 1.28 ± 0.82 for Ninte-
danib and Pirfenidone, respectively; fold change upon
treatment) (Fig. 1g). Both drugs exhibited similar effects
on fibrotic gene expression in 3D-LTCs derived from
PBS treated mice, except no significant effect on Colla-
gen 1 secretion (Additional file 2: Figure S2A-C). Over-
all, these data confirm the previous reported anti-fibrotic
effects of Pirfenidone and Nintedanib in experimental
lung fibrosis models in vivo in an ex vivo tissue culture
model and demonstrate that 3D-LTCs can be applied to
further investigate the effect of both drugs on cellular
phenotypes and function. Hereafter, we used concentra-
tions of 1 μM Nintedanib and 500 μM Pirfenidone as
these concentrations have been widely used and recom-
mended in in vitro studies [18] and showed anti-fibrotic
activity in our ex vivo model (statistically significant for
Nintedanib; trend for Pirfenidone).
While the anti-fibrotic effects of both drugs have been
predominantly studied in fibroblasts [16–19, 22–24],
there is little knowledge about the effects of Nintedanib
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and Pirfenidone on the lung epithelium. We first
assessed changes of the functional ATII cell marker pro
surfactant protein C (SP-C) and found that Nintedanib
increased proSP-C protein expression (Fig. 2a) and
affected SP-C secretion in fibrotic 3D-LTCs (Fig. 2b and
Additional file 3: Figure S3A and B). In order to deter-
mine if Nintedanib treatment was also able to suppress
epithelial-derived pro-fibrotic mediator expression, we
A
E
G
B
D
F
C
Fig. 1 Effect of ex vivo treatment with Pirfenidone and Nintedanib on the fibrotic phenotype of 3D-LTCs. a Representative immunofluorescence
analysis of Collagen I, α-SMA and E-Cadherin in control (PBS) and fibrotic (Bleo) 3D-LTCs after 48 h in culture. Scale bar represents 50 μm. b Gene
expression analysis by qPCR of fibrotic marker Fn1 and Col1a1 in control and fibrotic 3D-LTCs after 48 h in culture. ΔCp relative to Hprt is
presented as mean ± SEM, n = 7. Means were compared using Wilcoxon matched pairs test. c Collagen I secretion of control and fibrotic 3D-LTCs
was determined by WB and normalized to supernatant volume. n = 6. Means were compared using Mann-Whitney test. d WISP1 secretion of
control and fibrotic 3D-LTCs was measured by ELISA. n = 7. Significance was assessed using Wilcoxon matched pairs test. e, f Fibrotic 3D-LTCs
were cultured for 48 h in the presence of anti-fibrotic drugs (e) Nintedanib (0.1 μM, 1 μM, 10 μM) (f) and Pirfenidone (100 μM, 500 μM, 2.5 mM).
Gene expression analysis by qPCR of fibrotic marker Fn1 and Col1a1. Log fold change is presented as mean ± SEM, n = 5–7. Means were
compared to respective DMSO control using one-sample t-tests in comparison to a hypothetical value of 0. g Collagen I secretion of fibrotic
3D-LTCs treated with Nintedanib (1 μM) and Pirfenidone (500 μM) for 48 h was determined by WB and normalized to supernatant volume. n = 5.
Significance was assessed using Wilcoxon matched pairs test. Significance: *p < 0.05, **p < 0.01
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examined secretion of WISP1, which was attenuated in
both fibrotic and normal 3D-LTCs by Nintedanib as
assessed by ELISA (Fig. 2c and Additional file: 3 Figure
S3C). In contrast, Pirfenidone did not consistently in-
duce SP-C secretion or proSP-C expression (Fig. 2a and
b), nor affected WISP1 secretion in fibrotic 3D-LTCs
(Fig. 2c). In order to rule out that higher Pirfenidone
concentrations could more consistently affect epithelial
cells, we tested a concentration of 2.5 mM Pirfenidone,
which did not show any significant effect on Sftpc gene
expression (Additional file: 3 Figure S3D).
Next, we aimed to validate these findings in fibrotic
pmATII cells (Fig. 3). As described previously [8], the
expression of Fn1 was significantly increased in cultured
pmATII cells derived from bleomycin-instilled mice
compared to the PBS control (PBS vs Bleo: 5.78 ± 0.04 vs
6.69 ± 0.37; relative gene expression) (Fig. 3a). We then
investigated gene expression changes of phenotypic and
functional ATII cell markers, including surfactant pro-
tein C (Sftpc), Nkx2.1 (thyroid transcription factor 1
(TTF-1)), ATI cell marker (T1a (Podoplanin)), and a
marker of a putative bi-potent progenitor population for
ATI and ATII cells (homeodomain only protein X
(Hopx)). Notably, fibrotic pmATII cells exhibited re-
duced expression of Sftpc as well as Nkx2.1 and Hopx
expression, whereas T1α (Podoplanin; a marker for ATI
cells;) was increased (Fig. 3b), likely representing
attempted repair by transdifferentiation of ATII to ATI
cells [31, 32]. Fn1 was significantly downregulated by
both Nintedanib and Pirfenidone in healthy and fibrotic
pmATII cells as assessed by qPCR (Fig. 3a). In line with
our previous observations in 3D-LTCs, treatment with
Nintedanib restored the expression of Sftpc, Nkx2.1 and
Hopx to the level of the PBS control (Fig. 3b). Pirfeni-
done treatment increased both Hopx and T1α but did
not affect ATII cell markers Sftpc and Nkx2.1 expression
(Fig. 3b).
Most mechanistic studies regarding Nintedanib or Pir-
fenidone have been performed on isolated cells or in
mice. We thus next investigated the effects of Ninteda-
nib (1 μM) and Pirfenidone (500 μM) in human
3D-LTCs and particularly focused on their effects on dis-
tal lung epithelial cell markers (Fig. 4). We recently de-
veloped a model that induces early fibrotic like changes
in human 3D-LTCs using a combination of four growth
factors and signaling molecules known to be elevated in
fibrosis (FC; TGF-β, PDGF-AB, TNF-α and LPA), (Add-
itional file 1: Figure S1, Fig. 4a) [25]. Induction of early
fibrosis-like changes in our cohort by FC was confirmed
by fibronectin deposition as evaluated by immunofluor-
escent staining (Fig. 4b). Importantly, treatment of
FC-treated 3D-LTCs with Nintedanib or Pirfenidone did
not alter metabolic activity as measured by WST-1 activ-
ity, suggesting that overall cell survival was not affected
(Fig. 4c, Additional file 4: Figure S4A). In line with our
previous findings, Nintedanib treatment restored epithe-
lial gene expression (Fig. 4d) as well as proSP-C protein
expression (Fig. 4e) and SP-C secretion (Fig. 4f ). In con-
trast, Pirfenidone did not affect epithelial cells in this
model (Additional file 4: Figure S4B and C). Overall,
Nintedanib upregulated ATII cell marker expression in
both murine and human 3D-LTCs and pmATII cells,
A
B C
Fig. 2 Effect of ex vivo treatment with Pirfenidone and Nintedanib on lung epithelial cell marker in fibrotic 3D-LTCs. a-c Fibrotic 3D-LTCs
were cultured for 48 h in the presence of anti-fibrotic drugs Nintedanib (1 μM) and Pirfenidone (500 μM). a proSP-C expression was
assessed by Western blot. β-Actin was used as loading control. Quantification of proSP-C Western blot, n = 6. Data was normalized to
β-Actin. b, c SP-C and WISP1 secretion of 3D-LTCs was determined by ELISA. n = 4–7. Significance was assessed using Wilcoxon matched
pairs test. Significance: *p < 0.05
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whereas Pirfenidone did not significantly affect the ex-
pression of the analyzed ATII cell markers in our study.
Discussion
IPF is a devastating interstitial lung disease, which pro-
gressively leads to lung destruction and loss of lung
function. Therapeutic options are limited, with two ap-
proved drugs, Pirfenidone and Nintedanib, which decel-
erate the loss of lung function compared to placebo
-treated patients [14, 15]. To date, there have been no
studies on living human lung tissue and thus we have
limited insights into their mode of action in humans. A
deeper and more comprehensive understanding of the
potential human target cells and target proteins of Nin-
tedanib and Pirfenidone may help in selecting which pa-
tients will respond better to which treatment and may
further allow for development of new drugs which are
designed to be more specific while at the same time re-
ducing off-target and side effects. 3D-LTCs are emerging
as a potential novel model, which can be used to bridge
pre-clinical data to the clinical data. Here, we report for
the first time anti-fibrotic activities of Pirfenidone and
Nintedanib in murine and human fibrotic 3D-LTCs ex
vivo and explored the effect of Nintedanib and Pirfeni-
done on alveolar epithelial cells. Notably, we provide evi-
dence that both drugs exhibit different effects on
alveolar epithelial cell behavior and function, with Ninte-
danib increasing in particular ATII cell markers.
Repetitive injury to the alveolar epithelium represents
a major pathomechanism in the development of IPF [2].
Aberrant responses of ATII cells have been shown to
contribute to impaired repair and regeneration pro-
cesses. However, development of novel therapeutic
agents has largely focused on targeting increased ECM
production and fibroblast accumulation. Several recent
studies underscore the suitability and effectiveness of
targeting aberrant epithelial cell responses in pulmonary
fibrosis [8, 13, 33–35]. Most mechanistic studies about
A
B
Fig. 3 Effect of in vitro treatment with Pirfenidone and Nintedanib on primary mouse (pm)ATII cells. a, b At day 14 after Bleomycin instillation,
mice were sacrificed and control (PBS) and fibrotic (Bleo) pmATII cells were harvested. The pmATII cells were cultured in the presence of
Nintedanib (1 μM) and Pirfenidone (500 μM) for 48 h. a Gene expression analysis by qPCR of fibrotic marker Fn1 in pmATII cells. ΔCp relative to
Hprt is presented as mean ± SEM, n = 3. Means were compared using repeated-measures one-way ANOVA followed by Newmann-Keuls post test.
b Gene expression analysis by qPCR of epithelial cell markers Sftpc, Nkx2.1, T1α, Hopx. ΔCp relative to Hprt is presented as mean ± SEM, n = 3.
Means were compared using repeated-measures one-way ANOVA followed by Newmann-Keuls post test. Significance: *p < 0.05, **p < 0.01,
***p < 0.001 (DMSO vs Pirfenidone/Nintedanib). Significance: #p < 0.05, ##p < 0.01, ###p < 0.001 (PBS vs Bleo)
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Fig. 4 (See legend on next page.)
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Pirfenidone and Nintedanib have thus far been per-
formed on fibroblasts [16–19, 21, 36, 37]. To date, we
know very little about how Nintedanib and Pirfenidone
influence other cell types in the lung in their natural 3D
composition, including epithelial cells. There is previous
evidence that Nintedanib decreases the proliferation of
vascular endothelial cells [20, 38]. Pirfenidone was found
to inhibit the shedding of microparticles [39], and Ninte-
danib increased SP-D expression in a human lung epi-
thelial cell line [40], however, these studies used
supraphysiologial concentrations of the drugs and are
thus of concern for interpreting these results in the con-
text of how these drugs might function in patients [41].
Two recent reports suggest an inhibition of EMT by
Nintedanib in ovarian cancer cells along with increased
E-cadherin levels [42, 43]. In line with these observa-
tions, we consistently found that Nintedanib improves
functional alveolar epithelial cell markers, such as SP-C,
in our study. These data suggest that restoring normal
alveolar epithelial cell function might contribute to the
anti-fibrotic effects of Nintedanib. Future studies using
relevant in vivo models will be required to further inves-
tigate and prove a potential causal relationship.
The use of Nintedanib and Pirfenidone in in vitro ex-
periments has been reported in a wide range of concen-
trations in the literature (up to 10 mM for Pirfenidone
and 5 μM for Nintedanib) [40, 44, 45]. After initial test-
ing of different concentrations in our 3D-LTC model, we
opted to use the drugs at concentrations that have been
widely used and recommended in in vitro studies (Nin-
tedanib: 1 μM and Pirfenidone: 500 μM) [18]. However,
the concentrations we used slightly exceed concentra-
tions measured in the patients’ plasma treated with ei-
ther drug (around 100 nM for Nintedanib and around
100 μM for Pirfenidone) [41, 46], and might thus be rep-
resentative of local concentrations of the drugs in the
lung. The availability of the drug in the 3D-LTCs might
differ as compared to in vitro or in vivo experiments due
to methodological reasons, nonetheless, our ability to
detect effects of the drug in our setup are encouraging
as to the applicability of the model for pre-clinical test-
ing of small molecules. Notably, while Nintedanib had
an effect on several epithelial cell marker, which have
been associated with distinct phenotypes, we did not ob-
serve a consistent effect of Pirfenidone across this same
panel of lung epithelial cell markers in our studies. This
might be due to limited concentrations and/or time
points that we were able to analyze, however, these data
further could indicate that individual patients exhibit dif-
ferent responses to Pirfenidone, which should be further
determined in larger cohorts.
While the ex vivo system includes many different cell
types and direct effects on non-epithelial cell types could
contribute to the observed changes in epithelial cells,
the effects we observed in pmATII cells suggests that
the increase in epithelial cell markers could be mediated
by a direct effect on these cells. Further studies aiming
to decipher the mechanism of how Nintedanib regulates
epithelial cell markers will be important to potentially
identify which patients may respond to which treatment.
One possible mechanism that might partially explain our
findings is that Nintedanib increased the expression of
the transcription factor Nkx2.1 in isolated pmATII cells
and in murine and human 3D-LTCs. Nkx2.1 is a critical
transcription factor in lung endoderm specification and
is known to control Sftpc gene expression in adult ATII
cells [47]. As we further observed increased expression
of other adult distal lung epithelial markers not regu-
lated by Nkx2.1, such as Hopx and Pdpn, other tran-
scriptional regulators such as Retinoid X receptors
(RXR) are likely involved [48].
3D-LTCs from rodents or human lung tissue have
gained increasing attention as disease models and for
preclinical validation of new therapeutics or in personal-
ized medicine approaches [25–28, 49]. 3D-LTCs spatially
retain the majority of the cellular diversity of the native
lung and allow for the analysis of tissue-level responses
to anti-fibrotic drugs in living tissue ex vivo. Moreover,
murine 3D-LTCs can be applied to extend mechanistic
studies, while reducing overall animal experimentation
[30]. Nevertheless, 3D-LTCs have certain limitations, for
example they lack appropriate control of air liquid inter-
faces, are not undergoing cyclic stretch and there is no
ability to recruit cells. This system does, however, offer
(See figure on previous page.)
Fig. 4 Ex vivo treatment with Nintedanib stimulates alveolar epithelial marker expression in the human 3D-LTCs model of early pulmonary
fibrosis. a Schematic of treatment with fibrotic cocktail (FC) or control cocktail (CC) and Nintedanib (Nint) and downstream analysis. 3D-LTCs were
generated and treated with FC or CC for 48 h before FC or CC treatment was replenished and Nintedanib or control treatment was added.
Treatment was stopped after 120 h and downstream experiments were performed. b Representative Immunofluorescence of punches treated
with CC or FC for 120 h and stained for Fibronectin. Scale bars represent 1 mm. c-f Punches were treated with CC/FC and Nintedanib (1 μM) as
indicated in (a). c Metabolic activity of punches 120 h after treatment with CC/FC and co-treatment with Nintedanib. N = 3. Significance was
assessed by two-way ANOVA followed by Sidak’s multiple comparisons test. d Gene expression analysis by qPCR of epithelial cell marker SFTPC,
NKX2.1, CDH-1, ZO-1. Log fold change is presented as mean ± SEM, N = 3. Means were compared to respective DMSO control using one-sample
t-tests in comparison to a hypothetical value of 0. e Representative Immunofluorescence of punches treated with FC and Nintedanib for proSP-C.
Scale bars represent 140um. f SP-C secretion of punches 120 h after treatment with CC/FC and co-treatment with Nintedanib was measured by
ELISA. Values shown are normalized to CC treatment. Significance was assessed using Wilcoxon matched pairs test. N = 6. Significance: *p < 0.05
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the unique opportunity to test drugs in the native hu-
man lung microenvironment. The evaluation of ap-
proved drugs, such as Nintedanib or Pirfenidone in
these emerging ex vivo models might pave the way for
further drug screening and validation for IPF. Fibrotic
3D-LTCs have been previously shown to maintain their
fibrotic phenotype in culture for up to 7 days [27]. Simi-
larly, we found that murine fibrotic slices derived from
the bleomycin model maintained elevated expression of
fibrotic markers after 48 h of culture. Here, we further
show that functional alveolar epithelial cell markers such
as SP-C were consistently downregulated over culture
thus indicating that alveolar injury upon bleomycin ex-
posure [50], is maintained ex vivo. These data underline
that murine 3D-LTCs can be applied as appropriate
models to study anti-fibrotic drugs in this timeframe, in-
cluding their effects on epithelial cells. Recent studies
have taken advantage of 3D lung slice cultures ex vivo.
Tatler et al. demonstrated that caffeine reduced estab-
lished fibrosis in 3D-LTCs from Bleomycin-instilled mice
[27], and IPF slices were used to determine the potential
therapeutic effect of a PI3K inhibitor [26]. Both studies
highlight the suitability of both mouse and human
3D-LTCs in the preclinical testing of anti-fibrotic drugs.
However, the effects of the approved drugs Pirfenidone
and Nintedanib on fibrotic 3D-LTCs have not been ex-
plored yet. Pirfenidone has been shown to reduce Colla-
gen1 expression in a rat slice model of liver fibrosis [51].
Similarly, in our bleomycin-induced fibrotic murine lung
slices, we found that Pirfenidone decreased fibrotic
markers. However, to date, there have been no ex vivo
studies in any tissue utilizing Nintedanib. Consistent
with in vivo experiments showing reduced collagen de-
position upon treatment [19], we show that Nintedanib
reduces established fibrotic markers in lung slices from
bleomycin-treated animals. Recent reports describe the
safety and tolerability of a combination treatment with
Pirfenidone and Nintedanib thus suggesting a future
treatment option for IPF patients [52]. Our study further
identifies differences in the mode of action of these two
drugs and further analysis on combined treatment in ex
vivo models will be helpful to gain further insight into
the potential rational for combining Nintedanib and Pir-
fenidone as well as other potential novel drugs.
While the use of human tissue for the generation of
3D-LTCs represents a unique possibility for a human
disease model [25, 26, 28, 49], one major limitation is
that access to IPF lung explants is limited and those
available for research typically represent only end-stage
disease. To test the effects of Nintedanib and Pirfeni-
done in human 3D-LTCs upon fibrotic remodeling, we
treated human 3D-LTCs with a combination of different
pro-fibrotic growth factors, pro-inflammatory cytokines
and signaling molecules that induce early fibrosis-like
features in human 3D-LTCs [25]. While the FC model
demonstrates robust changes in ECM remodeling, it is
important to highlight that further development and im-
provement of ex vivo 3D-LTC models to induce and re-
flect even more IPF-like fibrotic responses, for example
with respect to other environmental challenges, aging,
or genetic susceptibility, will be essential to allow the full
exploitation of these models to discover and confirm
novel drugs for the treatment of IPF.
Conclusion
In summary, we report that Nintedanib but not Pirfeni-
done treatment positively affects a wide panel of pheno-
typic markers of different alveolar epithelial cell types in
vitro and ex vivo, potentially contributing to its
anti-fibrotic activity. In addition, we demonstrate that
Nintedanib exhibits anti-fibrotic activity in an ex vivo
model of IPF using human tissue, further validating this
model for use in preclinical studies.
Additional files
Additional file 1: Figure S1. Generation of mouse and human 3D-LTCs.
Mouse lungs were harvested from PBS or Bleomycin treated mice or
cancer resections from human patients were collected and filled with 2
or 3% low melting agarose, respectively. 300 or 500 μm thin 3D-LTCs
were generated and cultured as indicated in each experiment.
(PDF 90 kb)
Additional file 2: Figure S2. Effect of Pirfenidone and Nintedanib on
fibrotic marker in healthy 3D-LTCs ex vivo. Mice were instilled with PBS
sacrificed at day 14. 3D-LTCs were generated and cultured for 48h. (A,B)
The non-fibrotic 3D-LTCs were cultured for 48h in the presence of
anti-fibrotic drugs (A) Nintedanib (0.1μM, 1μM, 10μM) (B) and Pirfenidone
(100μM, 500μM, 2.5mM). Gene expression analysis by qPCR of fibrotic
marker Fn1 and Col1a1. ΔΔCt relative to Hprt and respective DMSO
control is presented as mean ± SEM, n = 5-7. Means were compared to
respective DMSO control using one-sample t-tests in comparison to a
hypothetical value of 0. (C) Collagen I secretion of nonfibrotic 3D-LTCs
treated with Nintedanib (1μM) and Pirfenidone (500μM) was determined
by WB and normalized to supernatant volume. n = 5. Significance:
*p < 0.05, **p < 0.01. (PDF 166 kb)
Additional file 3: Figure S3. Effect of Pirfenidone and Nintedanib on
epithelial cell marker in non-fibrotic 3D-LTCs ex vivo (A-C) Fibrotic and non-
fibrotic 3D-LTCs were cultured for 48h in the presence of anti-fibrotic drugs
Nintedanib (1μM) and Pirfenidone (500μM). (A) proSP-C expression was
assessed by Western blot. β-Actin was used as loading control. Quantification
of proSP-C Western blot. Data was normalized to β-Actin. Significance was
assessed using Wilcoxon matched pairs test, n = 6. (B, C) SP-C and WISP 1 se-
cretion of non-fibrotic 3D-LTCs was determined by ELISA. Significance was
assessed using Wilcoxon matched pairs test, n = 4-7. (D) Fibrotic and non-
fibrotic 3D-LTCs were cultured for 48h in the presence of 2.5mM Pirfenidone.
Gene expression analysis by qPCR of ATII marker Sftpc. ΔCt is presented as
mean ± SEM, n = 5. Means were compared using repeated-measures
one-way ANOVA followed by Newmann-Keuls post test. Significance:
*p < 0.05. (PDF 748 kb)
Additional file 4: Figure S4. Effect of Pirfenidone on ex vivo human
PCLS model of IPF. (A-C) Punches were treated with CC/FC and
Pirfenidone (500 μM) as indicated in (Fig. 4a). (A) Metabolic activity of
punches 120h after treatment with CC/FC and cotreatment with
Pirfenidone. N = 3. Significance was assessed by two-way ANOVA
followed by Sidak’s multiple comparisons test. (B) Gene expression
analysis by qPCR of epithelial cell marker SFTPC, NKX2.1, CDH-1, ZO-1.
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ΔΔCt is presented as mean ± SEM, n = 3. Means were compared to
respective DMSO control using one-sample t-tests in comparison to a
hypothetical value of 0. (C) SP-C secretion was measured by ELISA. Shown
are values normalized to CC without Pirfenidone. Significance was
assessed using Wilcoxon matched pairs test. N = 6. (PDF 97 kb)
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